Target Validation Information | |||||
---|---|---|---|---|---|
Target ID | T38996 | ||||
Target Name | Phospholipase D1 | ||||
Target Type | Research |
||||
Drug Potency against Target | 1-(pyridin-4-yl)piperazine | Drug Info | IC50 = 3600 nM | [530029] | |
1-(pyridin-2-yl)piperazine | Drug Info | IC50 = 3600 nM | [530029] | ||
HALOPEMIDE | Drug Info | IC50 = 21 nM | [529914] | ||
Afimoxifene | Drug Info | IC50 = 4800 nM | [529914] | ||
References | |||||
Ref 530029 | Bioorg Med Chem Lett. 2009 Apr 15;19(8):2240-3. Epub 2009 Mar 6.Design and synthesis of isoform-selective phospholipase D (PLD) inhibitors. Part II. Identification of the 1,3,8-triazaspiro[4,5]decan-4-one privileged structure that engenders PLD2 selectivity. | ||||
Ref 530029 | Bioorg Med Chem Lett. 2009 Apr 15;19(8):2240-3. Epub 2009 Mar 6.Design and synthesis of isoform-selective phospholipase D (PLD) inhibitors. Part II. Identification of the 1,3,8-triazaspiro[4,5]decan-4-one privileged structure that engenders PLD2 selectivity. | ||||
Ref 529914 | Nat Chem Biol. 2009 Feb;5(2):108-17. Epub 2009 Jan 11.Design of isoform-selective phospholipase D inhibitors that modulate cancer cell invasiveness. | ||||
Ref 529914 | Nat Chem Biol. 2009 Feb;5(2):108-17. Epub 2009 Jan 11.Design of isoform-selective phospholipase D inhibitors that modulate cancer cell invasiveness. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.